Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Rhea-AI Summary
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ARMP declined 11.61%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
For more information: https://phagefuturesusa.com/events/phage-futures-2024
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-the-5th-annual-phage-futures-annual-meeting-302309391.html
SOURCE Armata Pharmaceuticals, Inc.